Aligos Therapeutics, Inc. (ALGS)

NASDAQ: ALGS · IEX Real-Time Price · USD

0.829

+0.005 (0.66%)

At close: Apr 24, 2024, 4:00 PM

0.820

-0.009 (-1.04%)

After-hours: Apr 24, 2024, 6:08 PM EDT

Aligos Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Revenue	15.53	13.91	4.36	0	0	0
Revenue Growth (YoY)	11.66%	219.04%	-	-	-	-
Gross Profit	15.53	13.91	4.36	0	0	0
Selling, General & Admin	30.62	26.41	28.53	17.94	10.01	3.21
Research & Development	73.04	85.08	104.15	79.89	44.04	10.46
Operating Expenses	103.66	111.49	132.68	97.83	54.04	13.66
Operating Income	-88.13	-97.58	-128.32	-97.83	-54.04	-13.66
Interest Expense / Income	-1.24	-1.64	-0.13	10.55	-1.86	0.27
Pretax Income	-86.88	-95.94	-128.19	-108.38	-52.18	-13.93
Income Tax	0.8	0.11	0.14	0.16	0.09	0
Net Income	-87.68	-96.05	-128.33	-108.54	-52.26	-13.93
Shares Outstanding (Basic)	64	43	40	10	2	11
Shares Outstanding (Diluted)	64	43	40	10	2	11
Shares Change	50.51%	7.13%	299.03%	397.62%	-81.93%	-
EPS (Basic)	-1.36	-2.25	-3.22	-10.87	-26.04	-1.25
EPS (Diluted)	-1.36	-2.25	-3.22	-10.87	-26.04	-1.25
Free Cash Flow	-79.02	-80.33	-116.55	-76.33	-49.55	-8.57
Free Cash Flow Per Share	-1.23	-1.88	-2.92	-7.64	-24.69	-0.77
Gross Margin	100.00%	100.00%	100.00%	-	-	-
Operating Margin	-567.50%	-701.66%	-2943.82%	-	-	-
Profit Margin	-564.61%	-690.63%	-2944.07%	-	-	-
Free Cash Flow Margin	-508.83%	-577.64%	-2673.87%	-	-	-
EBITDA	-85.06	-93.91	-124.54	-94.51	-51.74	-12.37
EBITDA Margin	-547.74%	-675.24%	-2857.15%	-	-	-
Depreciation & Amortization	3.07	3.68	3.78	3.33	2.3	1.29
EBIT	-88.13	-97.58	-128.32	-97.83	-54.04	-13.66
EBIT Margin	-567.50%	-701.66%	-2943.82%	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).